AB135. Efficacy of extracorporeal shock wave therapy for the treatment of Peyronie’s disease: a meta-analysis

Objective: Extracorporeal shock wave therapy (ESWT) is an attractive treatment for Peyronie’s disease (PD), while its effectivity for PD still remains controversial. Methods: We conducted a search of PubMed, MEDLINE, EMBASE for available literatures published before June 2014. To access the treatment of ESWT for PD in penile pain, plaque size, deviation angle, intercourse function. Results: Seven studies were finally assessed in our metaanalysis. When Compared ESWT with control for penile pain, the remission rate was significantly higher (OR =1.78, 95% CI, 1.34-2.35), unchanged pain rate were significantly less (OR =0.51, 95% CI, 0.30-0.89) and aggravation pain rate was less (OR =0.38, 95% CI, 0.12-1.17).The pooled odds risk for reduced deviation angle rate was (OR =1.36, 95% CI, 0.80-2.31) in the ESWT group vs control, which indicates no statistical significance. Contractible or disappeared plaque rate after ESWT were significantly higher than in control group (OR =2.42, 95% CI, 1.74-3.37). There was no significant difference for the rate of possible intercourse patients between ESWT and control group (OR =1.32, 95% CI, 0.42-4.17). Moderate intercourse rate were significantly lower after ESWT vs. control group (OR =0.65, 95% CI, 0.42-0.99). Impossible intercourse rate were no statistical significant difference (OR =0.811, 95% CI, 0.42-1.58). Conclusions: ESWT could alleviate penile pain and reduce or soften PD plaque. The intercourse or erectile function may subjectively improve after ESWT. However, there is no significant influence for penile deviation. More high-quality RCTs are required to verify the findings.